Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.

BACKGROUND:Despite their widespread use in this population, data on the pharmacodynamic (PD) properties of the insulin analogs detemir and glargine in severely obese patients with type 2 diabetes are lacking. METHODS:The primary objective of the study was to compare the PD properties of two differen...

Full description

Bibliographic Details
Main Authors: Stefan Bilz, Miriam Flückiger, Fabian Meienberg, Claudine Falconnier, Ulrich Keller, Jardena J Puder
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6095527?pdf=render